Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Marinus Pharmaceuticals, Inc.

http://marinuspharma.com/

Latest From Marinus Pharmaceuticals, Inc.

Deal Watch: Seagen Ups Presence In HER2-Positive Cancer Field With RemeGen Deal

Lilly partners with Kumquat to discover small molecule IO drug. Kite, Appia Bio collaborate on allogeneic cell therapies. AstraZeneca and Regeneron pursue novel metabolic therapies targeting GPR75. Lexeo and Stelios merge to focus on gene therapies for rare cardiovascular indications.

Deals M & A

Keeping Track: US FDA Approvals Of Saphnelo, Nexviazyme Balanced By CRLs For Rolontis, Treosulfan, Tenapanor

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.

US FDA Performance Tracker Approvals

After Years Of Setbacks, Marinus Closes In On Rare Epilepsy Opportunity

After multiple failed attempts to treat rare conditions, Marinus is on the cusp of success with ganaxolone in genetic epilepsy, and has secured a new European partner in Orion.

Commercial Companies

Orphan Drugs Dominate EU Fast-Track Request Decisions In July

The European Medicines Agency decided this month whether to grant fast-track review for planned marketing authorization applications for three potential new orphan treatments.

Europe Review Pathway
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Specialty Pharmaceuticals
  • Biotechnology
    • Nanotechnology, Chips, etc.
UsernamePublicRestriction

Register